Merck & Co
MRK
143.63
-2.32
-1.59%
Merck & Co
US · MRK
#43 by market cap
Listed 1970
143.63
-2.32
-1.59%
Live - 5344 symbols - heartbeat 450s ago
· 2026-10-20 08:19
Analyst consensus 19 analysts
Buy
Avg price target 165.06 +14.9%
Price target rangecurrent 143.63
Low125.00
Avg165.06
High180.00
Buy 74%
Hold 26%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-09 | UBS | -- | Buy | 175.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 163.00 |
| 2026-10-08 | Cantor Fitzgerald | -- | Hold | 145.00 |
| 2026-10-08 | BMO Capital | -- | Buy | 170.00 |
| 2026-10-07 | Morgan Stanley | -- | Buy | 177.00 |
| 2026-10-05 | J.P. Morgan | -- | Buy | 165.00 |
| 2026-09-30 | BMO Capital | -- | Buy | 170.00 |
| 2026-09-30 | Goldman Sachs | -- | Buy | 160.00 |
| 2026-09-29 | Scotiabank | -- | Buy | 180.00 |
| 2026-09-29 | RBC Capital | -- | Hold | 150.00 |
| 2026-09-25 | BMO Capital | -- | Buy | 170.00 |
| 2026-09-24 | UBS | -- | Buy | 175.00 |
| 2026-09-23 | BofA Securities | -- | Buy | 166.00 |
| 2026-09-23 | Scotiabank | -- | Buy | 155.00 |
| 2026-09-22 | TD Cowen | -- | Hold | 155.00 |
| 2026-09-21 | RBC Capital | -- | Hold | 150.00 |
| 2026-09-20 | Morgan Stanley | -- | Buy | 179.00 |
| 2026-09-14 | RBC Capital | -- | Hold | 150.00 |
| 2026-09-11 | DBS | -- | Buy | 180.00 |
| 2026-09-10 | HSBC | -- | Buy | 172.00 |
| 2026-09-10 | BofA Securities | -- | Buy | 166.00 |
| 2026-09-10 | Leerink Partners | -- | Buy | 161.00 |
| 2026-09-09 | Leerink Partners | -- | Buy | 161.00 |
| 2026-09-08 | Guggenheim | -- | Buy | 170.00 |
| 2026-09-07 | Barclays | -- | Hold | 168.07 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Buy
Analyst consensus
Buy
All 2 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 2
■ Upgrades■ Downgrades
- 2 upgrades vs 2 downgrades among tracked analyst rating changes.
- Most recent: Barclays moved from Buy to Hold on 2026-09-07.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-07 | Barclays | Buy → Hold | 168.07 |
| 2026-08-25 | RBC Capital | Buy → Hold | 150.00 |
| 2026-08-19 | Morgan Stanley | Hold → Buy | 179.00 |
| 2025-11-24 | Wells Fargo | Hold → Buy | 125.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | -- | ±4.46% | +0.18% (in line) |
| 2026/Q1 | 2026-04-30 | -- | ±4.16% | -1.60% (in line) |
| 2025/Q4 | 2026-02-03 | -- | ±4.61% | +2.18% (in line) |
| 2025/Q3 | 2025-10-30 | -- | ±3.90% | -0.35% (in line) |
| 2025/Q2 | 2025-07-29 | -- | ±5.03% | -1.70% (in line) |
| 2025/Q1 | 2025-04-24 | -- | ±5.74% | +1.40% (in line) |
| 2024/Q4 | 2025-02-04 | -- | ±5.13% | -9.07% (beat) |
| 2024/Q3 | 2024-10-31 | -- | ±4.89% | -2.39% (in line) |
| 2024/Q2 | 2024-07-30 | -- | ±4.24% | -9.81% (beat) |
| 2024/Q1 | 2024-04-25 | -- | ±3.15% | +2.93% (in line) |
| 2023/Q4 | 2024-02-01 | -- | ±2.53% | +4.64% (beat) |
| 2023/Q3 | 2023-10-26 | -- | ±2.76% | +1.85% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-20 08:19:56 · For reference only, not investment advice and not tailored to your situation.
the keytruda patent cliff is a few years out but the market’s already discounting it hard. pipeline needs to deliver or this stays cheap for a while, that’s the whole debate in one sentence.